Objectives
SECONDARY
The primary study objective was to assess the effect of adavosertib on the PKs of probe substrates for CYP3A (midazolam), CYP2C19 (omeprazole), and CYP1A2 (caffeine). The secondary study objectives were to: describe the PKs of midazolam, omeprazole, and caffeine and their respective metabolites (1ʹ-hydroxymidazolam [1ʹ-HM], 5-hydroxyomeprazole [5-HO], and paraxanthine) in the absence and presence of adavosertib; describe the PKs of adavosertib; and observe the clinical and laboratory safety and tolerability of adavosertib.